Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A After Keloid Scar Revision
NCT05072821Phase 4Completed
- Sponsor
- National Cheng Kung University Hospital
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of botulinum toxin type A in keloid (2 arms), sponsored by National Cheng Kung University Hospital. Primary endpoint: Keloid recurrence at 1 year. Started Oct 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
keloid
Beyond the preview
Go deeper on NCT05072821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072821.